NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab (MEDI4736) and Tremelimumab in Muscle-invasive Urothelial Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 26 Dec 2018
At a glance
- Drugs Cisplatin (Primary) ; Doxorubicin (Primary) ; Durvalumab (Primary) ; Methotrexate (Primary) ; Tremelimumab (Primary) ; Vinblastine (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NEMIO
- 17 Dec 2018 Status changed from not yet recruiting to recruiting.
- 19 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.
- 28 Aug 2018 Planned initiation date changed from 1 Jun 2018 to 1 Sep 2018.